Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 6/20 | 0.48 |
| ▸ | MAOA | P21397 | 2/20 | 0.42 |
| ▸ | CISD1 | Q9NZ45 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 5/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | MPC2 | O95563 | 1/20 | 0.37 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5167121 | 0.85 | KCNH2 (0.49) | FFAR1MAOACISD1MAPTPPARG | |
| SCHEMBL5169080 | 0.85 | PPARG (0.49) | FFAR1MAOACISD1MAPTPPARG | |
| SCHEMBL5167894 | 0.82 | PIK3CG (0.50) | FFAR1MAPTPPARGALDH1A1KDM4E | |
| SCHEMBL5168227 | 0.81 | RXRA (0.49) | FFAR1PPARGALDH1A1KDM4E | |
| SCHEMBL5167756 | 0.79 | FFAR1 (0.55) | FFAR1MAOACISD1MAPTPPARA | |
| SCHEMBL15356751 | 0.78 | FFAR1 (0.49) | FFAR1MAOACISD1MAPTPPARA | |
| SCHEMBL5451781 | 0.77 | HPGD (0.54) | FFAR1MAPTPPARGALDH1A1KDM4E | |
| SCHEMBL5167914 | 0.76 | INSR (0.42) | MAOACISD1MAPTPPARGALDH1A1 | |
| SCHEMBL6202350 | 0.74 | FFAR1 (0.73) | FFAR1MAOACISD1MAPTPPARA | |
| SCHEMBL12961874 | 0.71 | MTOR (0.35) | MAPTALDH1A1KDM4EPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1774958-A1 | Use of phenylfurylmethylthiazolidine-2,4-dione or phenylthienylmethylthiazolidine-2,4-dione compounds for promoting and/or inducing and/or stimulating the pigmentation of keratinous substances and/or limiting their depigmentation and/or their whitening | L'Oréal (FR) | 2007-04-18 | — | — | EP | claimed |
| EP-1775294-A1 | Phenyl-furyl-methyl-thiazolidine-2,4-dione or phenyl-thienyl-methyl-thiazolidine-2,4-dione compounds; use for stimulating or inducing keratin fibre growth and/or slowing down their loss; compostions thereof | L'Oréal (FR) | 2007-04-18 | — | — | EP | claimed |
| US-20070078175-A1 | Administration of novel phenylfurylmethylthiazolidine-2,4-dione and phenylthienylmethylthiazolidine-2,4-dione compounds for stimulating or inducing the growth of keratinous fibers and/or slowing loss thereof | L'OREAL (FR) | 2007-04-05 | — | — | US | claimed |
| US-20070077215-A1 | Administration of phenylfurymethylthiazolidine-2,4-dione or phenylthienymethylthiazolidine-2,4-dione compounds for promoting and/or inducing and/or stimulating the pigmentation of keratinous substances and/or limiting their depigmentation and/or their whitening | L'OREAL (FR) | 2007-04-05 | — | — | US | claimed |
| EP-1775294-A1 | Phenyl-furyl-methyl-thiazolidine-2,4-dione or phenyl-thienyl-methyl-thiazolidine-2,4-dione compounds; use for stimulating or inducing keratin fibre growth and/or slowing down their loss; compostions thereof | L'Oréal (FR) | 2007-04-18 | — | — | EP | disclosed |
| EP-1774958-A1 | Use of phenylfurylmethylthiazolidine-2,4-dione or phenylthienylmethylthiazolidine-2,4-dione compounds for promoting and/or inducing and/or stimulating the pigmentation of keratinous substances and/or limiting their depigmentation and/or their whitening | L'Oréal (FR) | 2007-04-18 | — | — | EP | disclosed |
| US-20070078175-A1 | Administration of novel phenylfurylmethylthiazolidine-2,4-dione and phenylthienylmethylthiazolidine-2,4-dione compounds for stimulating or inducing the growth of keratinous fibers and/or slowing loss thereof | L'OREAL (FR) | 2007-04-05 | — | — | US | disclosed |
| US-20070078175-A1 | Administration of novel phenylfurylmethylthiazolidine-2,4-dione and phenylthienylmethylthiazolidine-2,4-dione compounds for stimulating or inducing the growth of keratinous fibers and/or slowing loss thereof | L'OREAL (FR) | 2007-04-05 | — | — | US | disclosed |
| US-20070078175-A1 | Administration of novel phenylfurylmethylthiazolidine-2,4-dione and phenylthienylmethylthiazolidine-2,4-dione compounds for stimulating or inducing the growth of keratinous fibers and/or slowing loss thereof | L'OREAL (FR) | 2007-04-05 | — | — | US | disclosed |
| US-20070077215-A1 | Administration of phenylfurymethylthiazolidine-2,4-dione or phenylthienymethylthiazolidine-2,4-dione compounds for promoting and/or inducing and/or stimulating the pigmentation of keratinous substances and/or limiting their depigmentation and/or their whitening | L'OREAL (FR) | 2007-04-05 | — | — | US | disclosed |
| US-20070077215-A1 | Administration of phenylfurymethylthiazolidine-2,4-dione or phenylthienymethylthiazolidine-2,4-dione compounds for promoting and/or inducing and/or stimulating the pigmentation of keratinous substances and/or limiting their depigmentation and/or their whitening | L'OREAL (FR) | 2007-04-05 | — | — | US | disclosed |
| US-20070077215-A1 | Administration of phenylfurymethylthiazolidine-2,4-dione or phenylthienymethylthiazolidine-2,4-dione compounds for promoting and/or inducing and/or stimulating the pigmentation of keratinous substances and/or limiting their depigmentation and/or their whitening | L'OREAL (FR) | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070077215-A1 | Administration of phenylfurymethylthiazolidine-2,4-dione or phenylthienymethylthiazolidine-2,4-dione compounds for promoting and/or inducing and/or stimulating the pigmentation of keratinous substances and/or limiting their depigmentation and/or their whitening | TYR, KRT18, MITF | FFAR1 2943/4885MAOA 129/4885CISD1 888/4885 |
| US-20070078175-A1 | Administration of novel phenylfurylmethylthiazolidine-2,4-dione and phenylthienylmethylthiazolidine-2,4-dione compounds for stimulating or inducing the growth of keratinous fibers and/or slowing loss thereof | KRT18, NGF, FGF1 | FFAR1 2463/4885MAOA 3183/4885CISD1 3038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.